A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

Who May Qualify: - Participant aged 18 years or older - Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10% - Participant newly initiated deucravacitinib according to the label - Provided written willing to sign a consent form to participate in the study Who Should NOT Join This Trial: - Participating in or planning to participate in an interventional clinical trial - Concomitant use of other systemic treatments for psoriasis at baseline - Prior treatment of deucravacitinib Always talk to your doctor about whether this trial is right for you.